Methods for therapeutic vaccination

Details Methods for therapeutic vaccination Methods for therapeutic vaccination

2005-08-11

2010-10-05

Shukla, Ram R (Department: 1644)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

C435S252310, C435S252800, C435S253100, C435S254210, C435S258100, C435S320100, C514S04400A, C536S023500

Reexamination Certificate

active

07807441

ABSTRACT:
A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

REFERENCES:
patent: 5736142 (1998-04-01), Sette
patent: 2002/0090379 (2002-07-01), Mouritsen et al.
patent: 2006/0008465 (2006-01-01), Steinaa
patent: 378881 (1990-07-01), None
patent: 0427347 (1991-05-01), None
patent: WO 86/07383 (1986-12-01), None
patent: WO 95/05849 (1995-03-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO-96/19496 (1996-06-01), None
patent: WO 9640789 (1996-12-01), None
patent: WO 97/41227 (1997-11-01), None
patent: WO 98/23635 (1998-06-01), None
patent: WO 98/31398 (1998-07-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/10375 (1999-03-01), None
patent: WO 99/40188 (1999-08-01), None
Molhoj and Degan. Nature Biotechnology, 22(12): 1502, 2004.
Ridge, J.P. et al., “A conditional dendritic cell can be . . . ,” Nature, vol. 393, Jun. 4, 1998, pp. 474-478.
Mackey, M.F. et al., “Cutting edge: dendritic cells require . . . ,” The Journal of Immunology, vol. 161, pp. 2094-2098.
Mackey, Matthew F. et al., “Cutting Edge: Dedritic Celss Require Maturation via CD40 to Generate Protective Antitumor Immunity,” The Journal of Immunology, 1998, vol. 161, pp. 2094-2098.
Database NCBI [Online] Accession No. AAA24998, Apr. 26, 1993, retrieved from Locus HEAPRD accession M37487.1.
Database NCBI [Online] Accession No. AAD33252, Jun. 30, 2000, retreived from database Lucus AF125673 accession No. AF125673.1.
Condon, Cal et al., “DNA-based immunization by in vivo transfection of dendritic cells,” Nature Medicine, Oct. 1996, pp. 1122-1128, vol. 2, No. 10.
Marsh, Steven G. E. et al., “Nomenclature for Factors of the HLA System 2002,” Human Immunology, 2002, pp. 1213-1268, vol. 63.
Michalek, Michael T. et al., “A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation,” Nature, Jun. 10, 1993, pp. 552-554, vol. 363.
Donnes, Pierre et al., “Prediction of MHC class I binding peptides, using SVMHC,” BMC Bioinformatics, Sep. 11, 2002, 3:25.
Yang, Xiao-Dong et al.; “Eradication of . . . ” Cancer Research 59 1236-1243, Mar. 15, 1999.
Kass, Erik et al.; “Induction of . . . ” Cancer Research 59, 676-683, Feb. 1, 1999.
Vonderheide, Robert H. et al, “The telomerase catalytic subunit . . . ” Immunity vol. 10, 673-679 Jun. 1999.
Kikuchi, Megumi et al.; “Indentification of a . . . ”Int. J. Cancer: 81.459-466 1999.
Marchand,Marie et al.; “Tumor Regressions . . . ” Int. J. Cancer; 80. 219-230 1999.
Sandmaier, Brenda et al.; “Evidence of . . . ”Journal of Immunotherapy 22(1) :54-66 1999.
Matzinger, “Graft tolerance . . . ” Nature Medicine vol. 5, No. 6 Jun. 1999, pp. 616-617.
Wang, Rong-Fu et al.; “Cloning Genes . . . ” Science vol. 284, May 21, 1999, pp. 1351-1354.
Sanda, Martin G. et al.; “Recombinant Vaccina . . . ” Urology 53 (2) 1999, pp. 260-266.
Kirkin, Alexei F. et al.; “Melanoma-associated . . . ” APMIS 106:663-679, 1993.
Klotz, Theo et al.;“Selective Expression . . . ” Cancer May 15, 1998 vol. 82, No. 10, pp. 1897-1903.
Divigi,Chaitanya R. et al.;“Phase I/II . . . ” Clinical Cancer Research vol. 4, 2729-2739 Nov. 1998.
Ossendorp, Ferry et al.; “Specific T Helper . . . ”J. Exp. Med. vol. 187, No. 5, Mar. 2, 1998, pp. 693-702.
Jager, Elke wt al.;“Simultaneous Humoral . . . ”J.Exp. Med. vol. 187, No. 2, Jan. 19, 1998, pp. 265-270.
Southwood, Scott et al.; “Several Common . . . ” Journal of Immunology, 160, pp. 3363-3373.
Schoenberger, Stephen et al.; “T-cell help . . . ” Nature vol. 393, Jun. 4, 1998, pp. 480-483.
Bennett, Sally R.M. et al.;“Help for . . . ”Nature vol. 393, Jun. 4, 1998, pp. 478-460.
Lanzavecchia, Antonio:“License to Kill”Nature vol. 393, Jun. 4, 1998, pp. 413-414.
Wagner, Stephen N. et al.;“Analysis of . . . ”Cancer Immunol. Immunother (1997)44:239-247.
Jarvis, Gary A. et al;“Expression and function . . . ”Int. J.Cancer: 71. 1049-1055 1997.
Krox Susan J, et al.;“Yttrium-90-labeled . . . ”Clinical Cancer Research vol. 2, pp. 457-470 Mar. 1996.
Lapthorn,A.J. et al.;“Crystal structure . . . ”, Nature, vol. 369, Jun. 9, 1994, pp. 455-461.
Talwar,G.P. et al.;“A vaccine . . . ”Proc. Natl. Acad. Sci. vol. 91,pp. 8532-8536 Aug. 1994.
Moradi,Mark M. et al.;“Serum and . . . ”Cancer Oct. 13, 1993 vol. 72, No. 8.
Grondahal-Hansen,Jan et al.;“High levels . . . ” Cancer Research 54, 2513-2521, Jun. 1, 1993.
Israeli, Ron S. et al.;“Molecular cloning . . . ”Cancer Research 33,227-230, Jan. 13, 1993.
Hammer, Juergen et al.;“Promiscuous and . . . ” Cell, vol. 74,197-203 Jul. 16, 1993.
Ghosh, Ananta K, et al;“Molecular Cloning . . . ”Cell Growth vol. 7,1425-1434 Oct. 1996.
Gemel, Joanna et al.; “Structure and . . . ”Genomics 35, 253-257 (1996).
Dalum, Iben et al.; “Breaking of B Cell . . . ” Amer. Assoc. of Immunology pp. 4796-4804, 1996.
Murphy, G.P. et al.;“Measurement of . . . ”The Prostate 25 :266-271 (1996).
Tjoa, Benjamin et al.; Presentation od . . . The Prostate 28:65-69 (1996).
Abrams, Scott I. et al.;“Mutant ras . . . ”Seminars in Oncology vol. 23, No. 1 (Feb.) 1996:pp. 118-134.
Wright, George L. et al.;“Upregulation of . . . ”Urology 48 (2) 1996.
Rock, Edwin P. et al.“Immunology of a . . . ”Vaccine 1996 vol. 14, No. 16.
Murphy, gerald et al.;“Comparison of . . . ”Anticancer Research 15:1473-1480 (1995).
Ohnishi, Y et al.;“Prolonged survival . . . ”British J. of Cancer (1995) 71, 969-973.
Wiener, Louis M. et al.;“Phase I Trial . . . ”Cancer Research 55,4586-4593, Oct. 15, 1995.
MacArthur, Craig A. et al.;“FGF-8 Isoforms . . . ”Cell Growth vol. 6,817-825 Jul. 1995.
Salomon, David S. et al.; “Epidermal growth . . . ”Critical reviews in Oncology/Hematology 19 (1995) 183-232.
Crossley, Phillip H. et al.;“The mouse Fgf8 . . . ”Development 121, 439-451 (1995).
Rammensee, Hans-Georg et al.;“MHC ligands . . . ”Immunogentics (1995) 41: 178-228.
Zhu, Zhenping et al.;“Engineering high . . . ”Int. J. Cancer: 62,319-324 (1995).
Tjoa, Benhamin et al.;“In Vitro . . . ”The Prostate 27:63-69 (1995).
Wolfel, Thomas et al.;“A p16ink4a . . . ”Science vol. 269, Sep. 1, 1995.
Lewis, Jonathon J. et al.;“Definition of . . . ”Cancer Biology, vol. 6, 1995; pp. 321-327.
Lupu, Ruth et al.;“Interaction bewteen . . . ”Cancer Biology, vol. 6, 1995:pp. 135-145.
Falk, Kirsten et al.;“Pool sequencing of . . . ”Immonogenetics 39:230-242, 1994.
Kahn, Daniel et al.;“Radioimmumoscintigraphy . . . ”Journal of Urology vol. 152, 1490-1495 Nov. 1994.
Chicz, Roman M. et al.,“Specificity and . . . ”J. Exp. Med. vol. 178,

Affiliated with

Also associated with

Rating

Methods for therapeutic vaccination does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for therapeutic vaccination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for therapeutic vaccination will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4217086